Skip to main content
. 2018;89(3):321–331. doi: 10.23750/abm.v89i3.7718

Table 4.

More frequent adverse events from the retrospective integrated safety analysis of data from 1,035 SOF/VEL for 12 Weeks patients and control/placebo patients in ASTRAL-1, -2, and -3

Patients, n (%) SOF/VEL 12 weeks N=1035 Placebo 12 weeks N=116
Headache 296 (29) 33 (28)
Fatigue 217 (21) 23 (20)
Nausea 135 (13) 13 (11)
Insomnia 87 (8) 11 (9)
Nasopharyngitis 121 (12) 12 (10)
Cough 57 (6) 4 (3)
Irritability 49 (5) 4 (3)
Pruritus 33 (3) 5 (4)
Dyspepsia 33 (2) 4 (3)